[Therapy for seronegative spondyloarthropathy].
Takasaki
Yoshinari
Y
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000008:administration & dosage; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage; D015235:HLA-B Antigens; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000069285:Infliximab; D011239:Prednisolone / Q000008:administration & dosage; D012015:Reference Standards; D012217:Rheumatoid Factor; D025242:Spondylarthropathies / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D052246:Cyclooxygenase 2 Inhibitors; D015235:HLA-B Antigens; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D012217:Rheumatoid Factor; D011239:Prednisolone; D000069285:Infliximab